RAD June 2024 Abstracts and Posters
718 Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Sonja Ständer, Gil Yosipovitch, Brian S. Kim, H. Chih-ho Hong, Martin Metz, Hiroyuki Murota, Xing-Hua Gao, Marjolein de Bruin-Weller, Amy Praestgaard, Joseph Zahn, Simmi Wiggins
719 Modulating Nav1.8-expressing neurons offers promising direction to address symptoms of atopic dermatitis
Madeline C. Scoles, Jacqueline C. Wang, Winnie Sung, Mason Olivarez, Ellen Liu, Emmy Lev, Rishi B. Shah, Seongmin Kim, Nihal Kaplan, Amy S. Paller
720 Comparative analysis of the ABCB5 gene expression in perilesional vitiligo and normal skin biopsies
Verónica Mondragón-Luna, Martha Alejandra Morales Sanchez , Gabriela Rebeca Luna Palencia , Ricardo Jaime-Cruz , Ismael Vásquez-Moctezuma
721 Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
Amit G. Pandya, Khaled Ezzedine, Thierry Passeron, Nanja van Geel, Kurt Brown, Leandro Santos, Lois Erskine, Kofi Wagya, Andrew Blauvelt
722 Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial
Amit G. Pandya, Thierry Passeron, Andrew Blauvelt, Nanja van Geel, Kurt Brown, Lois Erskine, Zhenyi Xue, Khaled Ezzedine
723 Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Christos Tziotzios, Rodney Sinclair, Aleksandra Lesiak, Stephanie Mehlis, Misaki Kinoshita-Ise, Athanasios Tsianakas, Xin Luo, Ernest H Law, Robert Wolk, Mojgan Sadrarhami, Alexandre Lejeune
724 A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata
David Rosmarin, Neil Sadick, Timothy G. Rodgers, Edward Lain, Lawrence Osman, Stephen Schleicher, Adam Reich, Jacek C Szepietowski, Agnieszka Owczarczyk-Saczonek, Wojciech Baran, Bartlomiej Kwiek, Michal Torz, Jacek Zdybski, Sohail Chaudhry, Zachary Lee, Heng Xu, Yi Liu, Brian Lewis, Katie Mellskog, Lucinda M. Elko-Simms, Christie Fanton, Mary Tagliaferri, Jonathan Zalevsky, Charles W. Lynde
725 The TCS/TCI-free rate remains high and stable while on lebrikizumab for treatment of moderate-to-severe atopic dermatitis over 1 year
James Del Rosso, Audrey Nosbaum, Alexandra Golant, Takeshi Nakahara, Jenny E. Murase, Andrew Pink, Sonia Montmayeur, Meihua Qiao, Sherry Chen, Ignasi Pau-Charles, Thomas Bieber
726 Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis
Andrew Alexis, Ali Moiin, Jill Waibel, Paul Wallace, David Cohen, Vivian Laquer, Pearl Kwong, Amber Reck Atwater, Cynthia Harris, Jennifer Proper, Maria Silk, Evangeline Pierce, Sreekumar Pillai, Maria Jose Rueda, Angela Moore
727 Case series on real-world experience of biologics in the management of atopic dermatitis in paediatric population at King’s College Hospital, London
Dr Dhanashree Prabhu, Dr Emilia Williamson, Dr Angela Tew